A new clinical study funded by non-profit organisation JDRF has revealed that a hybrid day-night closed-loop insulin delivery system (artificial pancreas) can control blood sugar levels better than sensor-augmented pump therapy in type 1 diabetes patients.
The study was conducted by the University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science and Addenbrooke’s Hospital.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It evaluated the capability of the closed-loop insulin delivery system in enabling blood sugar control in poorly controlled patients when compared to sensor-augmented pump therapy.
Results showed that the proportion of time that glucose was in target range between 3·9 and 10mmol/l was significantly higher in the closed-loop group compared to sensor pump arm.
Also, subjects treated with the closed-loop systems experienced higher reductions in glycated haemoglobin (HbA1c) levels.
Sensor-augmented pump therapy involves a combination of an insulin pump with a continuous glucose monitoring sensor. The sensor transmits glucose readings to the person wearing the device, who will make all insulin-dosing decisions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHowever, closed-loop insulin delivery systems combine continuous glucose monitoring with an insulin pump and an algorithm that enables automated insulin delivery.
During the study, the researchers treated a total of 86 patients characterised by sub-optimal blood sugar control with a sensor-augmented pump or the closed-loop therapy.
Based on the findings, the researchers concluded that day-and-night hybrid closed-loop insulin delivery improves glycaemic control.
A statement from the team read: “The use of day-and-night hybrid closed-loop insulin delivery improves glycaemic control while reducing the risk of hypoglycaemia in adults, adolescents and children with type 1 diabetes compared to conventional pump therapy or sensor-augmented pump therapy.
“Results from our study together with those from previous studies support the adoption of closed-loop technology in clinical practice across all age groups.”
